MBX Biosciences, Inc.
MBX · XNASCIK 1776111fmd_1NGFKCTM7B3H4E1QGA50C2G73QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 29 | 57 | 79 |
| Total operating expenses | 35 | 68 | 98 |
| Operating income | (35) | (68) | (98) |
| Interest and investment income | 3 | 6 | 11 |
| Income before taxes | – | (62) | (87) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | – | (62) | (87) |
| Net income | (33) | (62) | (87) |
| Net income to common shareholders | (33) | (62) | (87) |